Enhanced efficacy in drug-resistant cancer cells through synergistic nanoparticle mediated delivery of cisplatin and decitabine.
Journal
Nanoscale advances
ISSN: 2516-0230
Titre abrégé: Nanoscale Adv
Pays: England
ID NLM: 101738708
Informations de publication
Date de publication:
17 Mar 2020
17 Mar 2020
Historique:
received:
28
10
2019
accepted:
26
01
2020
entrez:
22
9
2022
pubmed:
27
1
2020
medline:
27
1
2020
Statut:
epublish
Résumé
There are several limitations with monodrug cancer therapy, including poor bioavailability, rapid clearance and drug resistance. Combination therapy addresses these by exploiting synergism between different drugs against cancer cells. In particular, the combination of epigenetic therapies with conventional chemotherapeutic agents can improve the initial tumour response and overcome acquired drug resistance. Co-encapsulation of multiple therapeutic agents into a single polymeric nanoparticle is one of the many approaches taken to enhance therapeutic effect and improve the pharmacokinetic profile. In this study, different types of poly(lactic-
Identifiants
pubmed: 36133040
doi: 10.1039/c9na00684b
pii: c9na00684b
pmc: PMC9419023
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1177-1186Subventions
Organisme : Medical Research Council
ID : G1001497
Pays : United Kingdom
Informations de copyright
This journal is © The Royal Society of Chemistry.
Déclaration de conflit d'intérêts
There are no conflicts to declare.
Références
J Control Release. 2011 Aug 10;153(3):198-205
pubmed: 21663778
Nanomedicine. 2016 Oct;12(7):1919-1929
pubmed: 27184098
J Am Chem Soc. 2014 Aug 20;136(33):11748-56
pubmed: 25078892
Int J Pharm. 2018 Apr 5;540(1-2):132-149
pubmed: 29427746
Adv Drug Deliv Rev. 2009 Oct 5;61(12):1043-54
pubmed: 19651167
Int J Nanomedicine. 2017 Nov 23;12:8427-8442
pubmed: 29200853
Biomaterials. 2013 Oct;34(32):7905-12
pubmed: 23891514
Biochem Pharmacol. 2012 Apr 15;83(8):1104-11
pubmed: 22285912
Int J Nanomedicine. 2017 May 23;12:3913-3926
pubmed: 28579777
Eur J Pharm Sci. 2009 Jun 28;37(3-4):300-5
pubmed: 19491019
Trends Mol Med. 2015 Apr;21(4):223-32
pubmed: 25656384
Nanoscale. 2017 May 11;9(18):5975-5985
pubmed: 28440835
Br J Cancer. 2014 Jan 7;110(1):123-32
pubmed: 24178762
Front Pharmacol. 2016 Jun 28;7:185
pubmed: 27445821
J Am Chem Soc. 2014 Apr 23;136(16):5896-9
pubmed: 24724706
PLoS One. 2014 Nov 12;9(11):e112880
pubmed: 25391133
Mater Sci Eng C Mater Biol Appl. 2016 Sep 1;66:138-146
pubmed: 27207047
ACS Nano. 2017 Sep 26;11(9):8560-8578
pubmed: 28829568
Nano Today. 2017 Aug;15:91-106
pubmed: 29225665
Ther Deliv. 2010 Aug;1(2):323-34
pubmed: 22816135
Oncotarget. 2017 Jun 6;8(23):38022-38043
pubmed: 28410237
J Aerosol Sci. 2018 Nov;125:164-181
pubmed: 30662086
Am J Physiol Cell Physiol. 2014 Dec 15;307(12):C1071-80
pubmed: 25252947
Ann Transl Med. 2018 Jun;6(11):229
pubmed: 30023392
Cancer. 1975 Jan;35(1):98-110
pubmed: 162854
Sci Rep. 2016 Feb 15;6:21225
pubmed: 26876480
Proc Natl Acad Sci U S A. 2013 Nov 12;110(46):18638-43
pubmed: 24167294
Chem Soc Rev. 2012 Apr 7;41(7):2971-3010
pubmed: 22388185
Br J Cancer. 2009 Mar 10;100(5):758-63
pubmed: 19259094
J Clin Oncol. 2006 Jun 20;24(18):2786-92
pubmed: 16782917
Nanomedicine (Lond). 2013 May;8(5):687-98
pubmed: 23075285